Literature DB >> 12019791

Multiple transcription factor profiling by enzyme-linked immunoassay.

Z Shen1, J Peedikayil, G K Olson, P D Siebert, Y Fang.   

Abstract

Transcription factor-DNA interactions have been widely studied in the regulation of gene expression. We have established an enzyme-linked immunoassay platform to quantify specific transcriptionfactor-DNA interactions. In our assay, dsDNA immobilized on a 96-well plate captures the transcriptionfactor from the nuclear extract of mammalian cells. The DNA-bound transcription factor is detected and quantified by enzyme-linked immunoassay using a transcription factor-specific antibody. We have profiled multiple transcription factors involved in inflammation including NFkappaB p50, NFkappaB p65, c-Rel, c-Fos, CREB-1, and ATF-2. When compared with the traditional electrophoretic mobility shift assay, the enzyme-linked immunoassay shows a 10-fold higher sensitivity, eliminates the use of radioactivity, allows for a high-throughput format, and is faster.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019791     DOI: 10.2144/02325dd07

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  13 in total

1.  AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain.

Authors:  Barbara Costa; Dario Siniscalco; Anna Elisa Trovato; Francesca Comelli; Maria Luisa Sotgiu; Mariapia Colleoni; Sabatino Maione; Francesco Rossi; Gabriella Giagnoni
Journal:  Br J Pharmacol       Date:  2006-06-12       Impact factor: 8.739

2.  Akt fine-tunes NF-κB-dependent gene expression during T cell activation.

Authors:  Jing Cheng; Binh Phong; David C Wilson; Raphael Hirsch; Lawrence P Kane
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

3.  PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts.

Authors:  Tomohiro Hikata; Hironari Takaishi; Jiro Takito; Akihiro Hakozaki; Mitsuru Furukawa; Shinichi Uchikawa; Tokuhiro Kimura; Yasunori Okada; Masahito Matsumoto; Akihiko Yoshimura; Riko Nishimura; Sakamuri V Reddy; Hiroshi Asahara; Yoshiaki Toyama
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

4.  Plate capture assay of fluorescent oligonucleotide duplex reporter-transcription factor complexes.

Authors:  Surong Zhang; Alexei Bogdanov
Journal:  Bioconjug Chem       Date:  2009-07-02       Impact factor: 4.774

5.  The role of Akt signaling in oxidative stress mediates NF-kappaB activation in mild transient focal cerebral ischemia.

Authors:  Yun Seon Song; Purnima Narasimhan; Gab Seok Kim; Joo Eun Jung; Eun-Hee Park; Pak H Chan
Journal:  J Cereb Blood Flow Metab       Date:  2008-07-16       Impact factor: 6.200

6.  Pyruvate protects against experimental stroke via an anti-inflammatory mechanism.

Authors:  Qing Wang; Michael van Hoecke; Xian Nan Tang; Hokyou Lee; Zheng Zheng; Raymond A Swanson; Midori A Yenari
Journal:  Neurobiol Dis       Date:  2009-07-25       Impact factor: 5.996

7.  Quantitative, solution-phase profiling of multiple transcription factors in parallel.

Authors:  Betul Bilgin; Li Liu; Christina Chan; S Patrick Walton
Journal:  Anal Bioanal Chem       Date:  2013-01-30       Impact factor: 4.142

8.  Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.

Authors:  Mariateresa Fulciniti; Pierfrancesco Tassone; Teru Hideshima; Sonia Vallet; Puru Nanjappa; Seth A Ettenberg; Zhenxin Shen; Nipun Patel; Yu-Tzu Tai; Dharminder Chauhan; Constantine Mitsiades; Rao Prabhala; Noopur Raje; Kenneth C Anderson; David R Stover; Nikhil C Munshi
Journal:  Blood       Date:  2009-05-05       Impact factor: 22.113

9.  A new microsphere-based immunoassay for measuring the activity of transcription factors.

Authors:  Yu-Ling Lin; Yun-Ju Lai; Tai-Chu Peng; Ru-Ping Lee; Kuang-Wen Liao; Nu-Man Tsai; Yen-Ku Liu; Chueh-Jen Tsai
Journal:  Biol Proced Online       Date:  2010-04-14       Impact factor: 3.244

10.  GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation.

Authors:  Jill M Seargent; Elisabeth A Yates; Jason H Gill
Journal:  Br J Pharmacol       Date:  2004-11-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.